Regenerative care
Platelet-rich plasma (PRP)
Uses a small sample of your own blood to concentrate platelets for provider-guided joint, tendon, skin, or hair care.
Explore offerings
Provider-first care, wellness, and treatment offerings.
Explore current and pending offerings in our provider network. A provider confirms availability, suitability, and next steps before any care or treatment is arranged.
Testing
TM Flow testing
A noninvasive check of circulation and automatic nerve signals that can help guide your next steps.
Testing
CBS Testing
A clinic screening test that helps your care team decide what to check next.
Provider consultation
Ketamine infusion consultation
A consultation for closely monitored ketamine infusion care for certain mood or pain conditions.
Wellness services
Customized IV infusion
A provider-prepared IV of fluids and nutrients tailored to your visit.
Availability being confirmed
BPC-157
Often sought for injury recovery and gut-health goals. This offering is still under clinical and legal review.
Availability being confirmed
TB4
Often sought for injury recovery and gut-health goals. This offering is still under clinical and legal review.
Availability being confirmed
BPC / TB blend
A recovery-focused blend often sought for injury and mobility goals. This offering is still under clinical and legal review.
Availability being confirmed
NAD+
A coenzyme your cells use to make energy, being reviewed for provider-guided wellness care.
Availability being confirmed
GHK-Cu
Often discussed for skin, scalp, and hair-care goals. This offering is still under clinical and legal review.
Availability being confirmed
GLP / GIP (tirzepatide)
A prescription medication used for weight-management and blood-sugar care when a clinician determines it fits.
Awaiting authorization
Retatrutide (triple G)
Not available. It cannot be compounded or offered until its authorization status changes.
Availability being confirmed
Tesamorelin
Used to reduce excess abdominal fat in adults with HIV-related lipodystrophy; it is not a general weight-loss drug.
Availability being confirmed
Tesamorelin / Ipamorelin
Often sought for sleep, recovery, and body-composition goals. This blend is still under clinical and legal review.
Availability being confirmed
CJC-1295 / Ipamorelin
Often sought for recovery, sleep, and body-composition goals. This blend is still under clinical and legal review.
Illustrative information only—not medical advice or a promise of results. Read more
Peptide information and safety notice
Some peptide descriptions on this page refer to common areas of interest, such as recovery, skin and hair, sleep, body composition, energy, or weight care. They are not a statement that a product is FDA-approved for that purpose, safe or effective for every person, or likely to produce a particular result.
Before any peptide may be prescribed or arranged, a licensed clinician must confirm the exact ingredient, formulation, source, legal availability, intended use, risks, drug interactions, suitability, and follow-up plan. Availability may change without notice. No one should start, stop, or change a medication based on this page.
Compounded and unapproved products
Compounded drugs are not FDA-approved. FDA does not review them before marketing for safety, effectiveness, or quality. Some peptide substances listed here have limited human safety information or FDA-identified concerns about impurities or immune reactions. We do not treat a product’s appearance in this catalog as an approval to dispense it.
Current regulatory watch
- FDA’s July 2026 Pharmacy Compounding Advisory Committee meeting discussed BPC-157-related and TB-500-related bulk substances. Committee review and public comments are not FDA approval or a permission to market a product.
- FDA says Retatrutide cannot be used in compounding under federal law and has not been found safe and effective for any condition. It remains unavailable in this marketplace.
- FDA has proposed excluding tirzepatide, semaglutide, and liraglutide from the 503B bulk-drug list; any future availability must follow the law and the clinician/pharmacy workflow in effect at that time.
- We reviewed 2026 HHS Secretary Robert F. Kennedy, Jr. congressional testimony and found broad research and regulatory-policy discussion, not a peptide-specific authorization for this marketplace. A hearing, advisory committee, or policy initiative does not make an offering approved or available.
Read the primary sources: FDA advisory committee notice, FDA peptide safety risks, FDA GLP-1 and Retatrutide notice, and HHS Secretary testimony.